Clinical trials are bureaucratic, opaque, and offputting to researchers and patients, MPs hearBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f1711 (Published 14 March 2013) Cite this as: BMJ 2013;346:f1711
- Adrian O’Dowd
Clinical trials are still too bureaucratic, not transparent enough, and offputting to potential researchers as well as participants, MPs have been told.
The clinical trials system and governing regulations in the United Kingdom must be improved, expert witnesses told the House of Commons Science and Technology Committee at an evidence session held on 13 March.
The committee is holding an inquiry into clinical trials, given that the European Commission is proposing to revise the directive that regulates trials in the UK. The inquiry also comes amid concerns raised about transparency and disclosure of all clinical trial data: drug companies are entitled to conduct numerous clinical trials on drugs but publish results selectively.
The MPs asked whether there was real evidence of some trial …
Log in using your username and password
Log in through your institution
Sign up for a free trial